Pharmaxis’s Bronchitol Wins U.K. Cost Agency's Backing

Pharmaxis Ltd.’s (PXS) Bronchitol won the backing of the U.K.’s health-cost regulator for use in some patients with cystic fibrosis, a rare genetic illness.

The drug may be used for adults who can’t use other treatments and whose lung function is rapidly declining, the London-based National Institute for Health and Clinical Excellence, known as NICE, said in a statement on the final draft recommendations. The agency reversed a decision from June, in which the agency said it couldn’t back the drug because of “gaps and uncertainties in the evidence on its effectiveness.”

The agency advises the National Health Service on which treatments represent value for money. Final guidance on Bronchitol, also known as mannitol, is expected to be published in November, NICE said.

“Following the helpful responses received during consultation on the draft guidance, the committee concluded that mannitol was a good use of NHS resources when treatment was offered to those who cannot use hypertonic saline or rhDNase and whose lung function is rapidly declining,” the agency said.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.